12:00 AM
 | 
Mar 22, 1999
 |  BC Week In Review  |  Company News  |  Deals

Biosite Diagnostics Inc., Scios deal

BSTE will use its Omniclonal antibody technology to help SCIO characterize cardiovascular disease targets identified through SCIO's...

Read the full 61 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >